Literature DB >> 3781984

Respiratory distress and surfactant inhibition following vagotomy in rabbits.

D Berry, M Ikegami, A Jobe.   

Abstract

We used the model of bilateral cervical vagotomy of adult rabbits to cause respiratory failure characterized by pulmonary edema, decreased lung compliance, and atelectasis. We documented an 18-fold increase in radiolabeled albumin leak from the vascular space into alveolar washes of vagotomy vs. sham-operated rabbits (P less than 0.01). Despite a twofold increase in percent of prelabeled saturated phosphatidylcholine secreted (P less than 0.01), the alveolar wash saturated phosphatidylcholine pool sizes were not different. The minimum surface tensions were 19.6 +/- 2.5 vs. 9.4 +/- 2.2 dyn/cm for alveolar washes from vagotomy and control rabbits, respectively (P less than 0.01). The soluble proteins from alveolar washes inhibited the surface tension lowering properties of natural surfactant, whereas those from the control rabbits did not (P less than 0.01). When vagotomy rabbits in respiratory failure were treated with 50 mg natural surfactant lipid per kilogram arterial blood gas values and compliances improved relative to control rabbits. Vagotomy results in alveolar pulmonary edema, and surfactant dysfunction despite normal surfactant pool sizes and respiratory failure. A surfactant treatment can improve the respiratory failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3781984     DOI: 10.1152/jappl.1986.61.5.1741

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  10 in total

1.  Exogenous surfactant treatment for the adult respiratory distress syndrome? A historical perspective.

Authors:  N S Morton
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

2.  Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.

Authors:  M Gupta; J M Hernandez-Juviel; A J Waring; F J Walther
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 3.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

Review 4.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

5.  Alveolar injury and regeneration following deletion of ABCA3.

Authors:  Tara N Rindler; Courtney A Stockman; Alyssa L Filuta; Kari M Brown; John M Snowball; Wenjia Zhou; Ruud Veldhuizen; Erika M Zink; Sydney E Dautel; Geremy Clair; Charles Ansong; Yan Xu; James P Bridges; Jeffrey A Whitsett
Journal:  JCI Insight       Date:  2017-12-21

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Effects of pulmonary stretch reflex on lung injury in rabbits with acute respiratory distress syndrome.

Authors:  Xiao-Yan Wu; Ying-Zi Huang; Huo-Gen Liu; Dong-Ya Huang; Rui Tang; Hai-Bo Qiu
Journal:  World J Emerg Med       Date:  2011

Review 8.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

Review 9.  Surfactant alteration and replacement in acute respiratory distress syndrome.

Authors:  A Günther; C Ruppert; R Schmidt; P Markart; F Grimminger; D Walmrath; W Seeger
Journal:  Respir Res       Date:  2001-10-12

Review 10.  Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects.

Authors:  W Seeger; A Günther; H D Walmrath; F Grimminger; H G Lasch
Journal:  Clin Investig       Date:  1993-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.